[Commercial Synthesis Spotlight] Process Optimization of Sotorasib’s Key Intermediate rac-4

rac-4 is a key intermediate in the synthesis of Sotorasib (AMG 510), the first-in-class KRAS G12C inhibitor approved for the treatment of various solid tumors, including non-small cell lung cancer (NSCLC).

[New Drug Spotlight] Ensifentrine - A New Dual PDE3/4 Inhibitor Approved for COPD Treatment

Ensifentrine (trade name: Ohtuvayre) was approved by the U.S. FDA in June 2024 as a maintenance treatment for adult patients with COPD.